Effect of Methocarbamol on Acute Pain After Traumatic Injury

Ohoud Aljuhani, Brian J. Kopp, Asad E. Patanwala

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

There is interest in the use of methocarbamol as an adjunctive agent for pain control after traumatic injury. The primary objective of this study was to determine the effect of methocarbamol on pain measurements after acute injury. This was a retrospective, matched cohort study conducted at an academic medical center in the United States. Consecutive adult (age ≥18 years) patients who were admitted to the hospital between June 1, 2012 and June 30, 2013 because of a traumatic injury were evaluated. Patient cases receiving methocarbamol for at least 3 days were matched to controls that did not receive methocarbamol based on age, sex, and injury severity. The primary outcome measures of pain scores were assessed on numerical rating scale from 0 to 10 (0 = no pain; 10 = worst possible pain) and conducted during routine patient care. A total of 200 patients were included in the final cohort (100 in each group). In the overall cohort, the mean age was 49 ± 22 years, 67% were men, and mean International Classification of Disease-derived Injury Severity Score was 0.8 ± 0.1 in both groups. There was no significant association between methocarbamol use and mean pain score on day 1 [coefficient 0.09, 95% confidence interval (CI), -0.57 to 0.75, P = 0.782, model R = 0.43], day 2 (coefficient 0.47, 95% CI, -0.15 to 1.09, P = 0.140, model R = 0.42), or day 3 (coefficient 0.51, 95% CI, -0.13 to 1.16, P = 0.117, model R = 0.42) after injury. Methocarbamol did not improve pain control after traumatic injury during the first 3 days of hospitalization.

Original languageEnglish (US)
Pages (from-to)e202-e206
JournalAmerican Journal of Therapeutics
Volume24
Issue number2
DOIs
StatePublished - Mar 1 2017

Fingerprint

Methocarbamol
Acute Pain
Pain
Wounds and Injuries
Confidence Intervals
Injury Severity Score
International Classification of Diseases
Pain Measurement
Patient Care
Hospitalization
Cohort Studies
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Effect of Methocarbamol on Acute Pain After Traumatic Injury. / Aljuhani, Ohoud; Kopp, Brian J.; Patanwala, Asad E.

In: American Journal of Therapeutics, Vol. 24, No. 2, 01.03.2017, p. e202-e206.

Research output: Contribution to journalArticle

Aljuhani, Ohoud ; Kopp, Brian J. ; Patanwala, Asad E. / Effect of Methocarbamol on Acute Pain After Traumatic Injury. In: American Journal of Therapeutics. 2017 ; Vol. 24, No. 2. pp. e202-e206.
@article{ebbc7f3e50e14a329c552f1dd1c0085b,
title = "Effect of Methocarbamol on Acute Pain After Traumatic Injury",
abstract = "There is interest in the use of methocarbamol as an adjunctive agent for pain control after traumatic injury. The primary objective of this study was to determine the effect of methocarbamol on pain measurements after acute injury. This was a retrospective, matched cohort study conducted at an academic medical center in the United States. Consecutive adult (age ≥18 years) patients who were admitted to the hospital between June 1, 2012 and June 30, 2013 because of a traumatic injury were evaluated. Patient cases receiving methocarbamol for at least 3 days were matched to controls that did not receive methocarbamol based on age, sex, and injury severity. The primary outcome measures of pain scores were assessed on numerical rating scale from 0 to 10 (0 = no pain; 10 = worst possible pain) and conducted during routine patient care. A total of 200 patients were included in the final cohort (100 in each group). In the overall cohort, the mean age was 49 ± 22 years, 67{\%} were men, and mean International Classification of Disease-derived Injury Severity Score was 0.8 ± 0.1 in both groups. There was no significant association between methocarbamol use and mean pain score on day 1 [coefficient 0.09, 95{\%} confidence interval (CI), -0.57 to 0.75, P = 0.782, model R = 0.43], day 2 (coefficient 0.47, 95{\%} CI, -0.15 to 1.09, P = 0.140, model R = 0.42), or day 3 (coefficient 0.51, 95{\%} CI, -0.13 to 1.16, P = 0.117, model R = 0.42) after injury. Methocarbamol did not improve pain control after traumatic injury during the first 3 days of hospitalization.",
author = "Ohoud Aljuhani and Kopp, {Brian J.} and Patanwala, {Asad E.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1097/MJT.0000000000000364",
language = "English (US)",
volume = "24",
pages = "e202--e206",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Effect of Methocarbamol on Acute Pain After Traumatic Injury

AU - Aljuhani, Ohoud

AU - Kopp, Brian J.

AU - Patanwala, Asad E.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - There is interest in the use of methocarbamol as an adjunctive agent for pain control after traumatic injury. The primary objective of this study was to determine the effect of methocarbamol on pain measurements after acute injury. This was a retrospective, matched cohort study conducted at an academic medical center in the United States. Consecutive adult (age ≥18 years) patients who were admitted to the hospital between June 1, 2012 and June 30, 2013 because of a traumatic injury were evaluated. Patient cases receiving methocarbamol for at least 3 days were matched to controls that did not receive methocarbamol based on age, sex, and injury severity. The primary outcome measures of pain scores were assessed on numerical rating scale from 0 to 10 (0 = no pain; 10 = worst possible pain) and conducted during routine patient care. A total of 200 patients were included in the final cohort (100 in each group). In the overall cohort, the mean age was 49 ± 22 years, 67% were men, and mean International Classification of Disease-derived Injury Severity Score was 0.8 ± 0.1 in both groups. There was no significant association between methocarbamol use and mean pain score on day 1 [coefficient 0.09, 95% confidence interval (CI), -0.57 to 0.75, P = 0.782, model R = 0.43], day 2 (coefficient 0.47, 95% CI, -0.15 to 1.09, P = 0.140, model R = 0.42), or day 3 (coefficient 0.51, 95% CI, -0.13 to 1.16, P = 0.117, model R = 0.42) after injury. Methocarbamol did not improve pain control after traumatic injury during the first 3 days of hospitalization.

AB - There is interest in the use of methocarbamol as an adjunctive agent for pain control after traumatic injury. The primary objective of this study was to determine the effect of methocarbamol on pain measurements after acute injury. This was a retrospective, matched cohort study conducted at an academic medical center in the United States. Consecutive adult (age ≥18 years) patients who were admitted to the hospital between June 1, 2012 and June 30, 2013 because of a traumatic injury were evaluated. Patient cases receiving methocarbamol for at least 3 days were matched to controls that did not receive methocarbamol based on age, sex, and injury severity. The primary outcome measures of pain scores were assessed on numerical rating scale from 0 to 10 (0 = no pain; 10 = worst possible pain) and conducted during routine patient care. A total of 200 patients were included in the final cohort (100 in each group). In the overall cohort, the mean age was 49 ± 22 years, 67% were men, and mean International Classification of Disease-derived Injury Severity Score was 0.8 ± 0.1 in both groups. There was no significant association between methocarbamol use and mean pain score on day 1 [coefficient 0.09, 95% confidence interval (CI), -0.57 to 0.75, P = 0.782, model R = 0.43], day 2 (coefficient 0.47, 95% CI, -0.15 to 1.09, P = 0.140, model R = 0.42), or day 3 (coefficient 0.51, 95% CI, -0.13 to 1.16, P = 0.117, model R = 0.42) after injury. Methocarbamol did not improve pain control after traumatic injury during the first 3 days of hospitalization.

UR - http://www.scopus.com/inward/record.url?scp=85015355669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015355669&partnerID=8YFLogxK

U2 - 10.1097/MJT.0000000000000364

DO - 10.1097/MJT.0000000000000364

M3 - Article

VL - 24

SP - e202-e206

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 2

ER -